In Reply We appreciate Akamatsu for addressing some important points regarding our first prospective study evaluating the efficacy and safety of immunotherapy and concurrent radiotherapy for locally advanced non–small cell lung cancer (NSCLC) without chemotherapy.¹ First, we fully agree with the comments by Akamatsu, suggesting that the inclusion of locally advanced recurrence may overestimate the efficacy outcome. That is why we mentioned in the Discussion that immunoradiotherapy is likely to have a greater effect for postoperative recurrence and stated this in the Limitations. Because postoperative recurrence was allowed in the PACIFIC trial,² it was also allowed in the trial. As a result, a large number (25.7%) of postoperative recurrences were enrolled.